KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin (2016 - 2025)

Neogenomics' Gross Margin history spans 16 years, with the latest figure at 43.83% for Q4 2025.

  • For Q4 2025, Gross Margin fell 109.0% year-over-year to 43.83%; the TTM value through Dec 2025 reached 43.21%, down 71.0%, while the annual FY2025 figure was 43.21%, 71.0% down from the prior year.
  • Gross Margin reached 43.83% in Q4 2025 per NEO's latest filing, up from 42.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 44.92% in Q4 2024 to a low of 32.63% in Q1 2022.
  • Average Gross Margin over 5 years is 40.73%, with a median of 41.45% recorded in 2023.
  • The largest YoY upside for Gross Margin was 1133bps in 2021 against a maximum downside of -960bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 35.99% in 2021, then increased by 14bps to 40.97% in 2022, then rose by 6bps to 43.45% in 2023, then grew by 3bps to 44.92% in 2024, then fell by -2bps to 43.83% in 2025.
  • Per Business Quant, the three most recent readings for NEO's Gross Margin are 43.83% (Q4 2025), 42.84% (Q3 2025), and 42.61% (Q2 2025).